



BioElevate

Turning early-stage health innovation into commercial direction

You've generated something novel in the lab.

You may have recently filed – or will be preparing to file – a patent.

Now comes the harder question: how does this become a real-world solution?

BioElevate is a two-day intensive designed for researchers who are new to commercialisation and ready to take their first structured step from discovery toward real-world impact.

BioElevate will take place 7-8 May 2026 at [Jumar Bioincubator](#), Melbourne

Why BioElevate?

Over two in-person days, you will:

- Clearly define and articulate your unmet clinical need
- Identify your critical stakeholders and decision-makers
- Develop a strong, defensible value proposition
- Understand market segmentation and early opportunity sizing (TAM/SAM/SOM)
- Map revenue streams and commercial pathways
- Gain practical clarity on regulation, IP positioning, and funding options
- Build your first structured pitch narrative
- Test your pitch with experienced VCs in a closed-door session designed for honest, constructive feedback.



Who Should Apply

BioElevate is designed for founders, researchers, or early-stage teams in:

- Therapeutics
- Medtech
- Diagnostics
- Software as a Medical Device (SaMD)

Applicants should:

- Be actively developing a technology or solution
- Have filed or thinking to file a patent
- Be at early Technology Readiness Level (typically TRL 1-3)
- Be new to commercialisation and ready to engage in the process

The Commitment

Researchers must attend both full in-person days (9AM - 5PM) in Melbourne and actively participate in all sessions and exercises.

BioElevate is high-engagement and working-session based, designed for capable teams (2 members per group) ready to take the first step into commercialisation.

The Facilitators

BioElevate is led by two experienced commercialisation practitioners active in digital, data, technology, and innovation sectors. There will also be special guest speakers, including a patent attorney, investment managers, and a startup biotech executive.



Dr Patricia Vietheer

Senior Director, R&D Strategy & Planning at Biointelect

At Biointelect, Patricia leads the R&D Strategy & Planning team, supporting a wide range of clients from universities, research institutions, government, start-up companies, biotech, medtech and pharma companies. She has led numerous projects at Biointelect in commercialisation strategy, business case development, planning and execution for key clients. She is particularly passionate about helping clients streamline their path to market using strategic project management techniques and thus commercialising their novel discoveries.

A/Prof Daryl Cheng

Consultant Paediatrician, Department of General Medicine
at The Royal Children's Hospital Melbourne

Associate Professor Daryl Cheng is a medical executive leader, digital health consultant and practicing consultant paediatrician and clinical informatician at The Royal Children's Hospital Melbourne (RCH) and Head of Paediatrics, Cabrini Health. Chief Medical Officer at Magentus, advising startups on digital health, data analytics, and transformation. He also contributes to systems innovation through roles with the Melbourne Children's Campus Centre for Health Analytics and the RCH Digital Innovation & Electronic Medical Record (EMR) Team.



The Expert Guests



Ian Rourke, PhD

Partner at FB Rice

Ian prepares and prosecutes patent applications internationally, evaluates the external patent landscape and intellectual property positions of competitors and conducts complex patent invalidity, infringement, due diligence and freedom-to-operate analyses. Awarded the title Most Client Focused IP Specialist at the 2017 Client Choice Awards, and a finalist in 2020, Ian has a substantial Australian client base including universities, research institutes, listed companies, and start-up companies. He has been recognised on the IAM Global Leaders list from 2023 to 2025, featured in the IAM Strategy 300 list for 2024 to 2025, and consistently endorsed on the IAM Prosecution Recommended list every year since 2018, achieving a 'Highly Recommended' status from 2022 to 2025.

VC Panel



Betty Zhang

Investment Manager at Boson Ventures

Betty is an Investment Manager at Boson Ventures, with a focus on early-stage venture investments in biotechnology, medical devices, and diagnostics across Australia. She is passionate about advancing deep tech and healthcare innovation through strategic investments, ecosystem development and bridging global resources.



Dr Ingmar Wahlqvist

Acting Chief Commercialisation Officer and leads the Monash Ventures team at Monash Innovation

Dr Ingmar is currently Acting Chief Commercialisation Officer and leads the Monash Ventures team at Monash Innovation. With a background as a medical doctor and an MBA, he brings over 20 years of experience in venture capital, strategy consulting, early-stage business creation and management, and pharmaceutical industry roles. His extensive expertise focuses on commercialisation and venture capital investment in biomedical and healthcare companies.



Dr Joey Man

Investment Associate at Tenmile

Joey Man is an Investment Associate with Tenmile based in Melbourne, where she enjoys working on a diverse portfolio of innovative technologies that have the potential to transform the biotech and medtech landscape. Joey holds a PhD in Molecular Biology from Monash University's Biomedicine Discovery Institute, her research focusing on breast cancer cell signalling and metastasis.

Places are limited. Early application is encouraged.

Don't miss out. Apply now!

If you have any questions, please email hello@jumarbio.com